Yossi Sherki-Gilgun

5 Basel Street
Petah Tiqwa, M 49131, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology.

Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology.

Journal: Hepatology (Baltimore, Md.)

Published: August 16, 2023

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Journal: British journal of clinical pharmacology

Published: January 29, 2018

Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.

Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.

Journal: Expert review of neurotherapeutics

Published: March 10, 2016

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Journal: Drug and alcohol dependence

Published: December 17, 2015

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Journal: Expert review of neurotherapeutics

Published: May 01, 2015

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.

Journal: BMC neurology

Published: March 20, 2015

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Journal: Journal of neurology

Published: November 25, 2014

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Journal: Journal of clinical pharmacology

Published: November 10, 2014

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Journal: Journal of neurology

Published: January 17, 2014

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Journal: Journal of neurology

Published: November 12, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026